*Female pelvic floor disorders*, an umbrella term including urinary incontinence, bladder storage symptoms, and pelvic organ prolapse (POP) are highly prevalent.[@bib1; @bib2] Almost one quarter of adult women report at least one clinically meaningful pelvic floor disorder,[@bib1; @bib3] with frequent overlap between conditions.[@bib4; @bib5] These conditions are associated with a range of comorbidities,[@bib6; @bib7; @bib8] and have a substantial impact on quality of life.[@bib9; @bib10; @bib11] There are strong associations with both age and obesity,[@bib12; @bib13; @bib14; @bib15] and thus the population burden of these conditions will increase with future demographic shifts.

The existence of inherited risk factors for pelvic floor disorders has been recognized for more than 150 years,[@bib16] and there is clear familial aggregation for these conditions. Having an affected first-degree relative with incontinence or prolapse is associated with an approximately 2- to 3-fold increased risk of developing either condition, with effects measurable for all major subtypes of incontinence, and for anterior, apical, and posterior compartment prolapse.[@bib17; @bib18; @bib19; @bib20; @bib21] A relevant family history is associated with both earlier onset, and more rapidly progressive symptoms.[@bib22; @bib23]

Family studies provide limited information on heritability, as they do not control for shared exposure to environmental risk factors. Twin studies have been used to formally quantify the heritability of lower urinary tract symptoms (LUTS) or prolapse. In a sample of 16,886 Swedish twins aged \>50 years, heritability was estimated as 41% for stress incontinence surgery, and 43% for prolapse surgery.[@bib24] Similarly for twins aged 20-46 years from the same cohort (n = 4550), heritability was estimated as 34% for stress incontinence, 37% for urgency incontinence, and 48% for nocturia.[@bib25] Among a cohort of 2336 women enrolled in the Danish Twin Register,[@bib26] heritability ranged with age from 42-49% for urgency incontinence, 27-55% for mixed incontinence, and up to 39% for stress incontinence.

Identification of the genetic variants underlying the heritability of these conditions would provide useful markers for clinical risk, prognosis, and treatment response. In addition, however, the insights provided should help explain the pathogenesis of these complex diseases, potentially offering new drug targets and preventative strategies. The aim of this systematic review was therefore to assess which candidate polymorphisms and/or candidate genes had been tested for an association with POP or LUTS in women, and to assess the strength, consistency, and potential for bias among published associations.

Materials and Methods {#sec1}
=====================

Eligibility criteria {#sec1.1}
--------------------

The review protocol was prospectively registered (PROSPERO 2011:CRD42012001983).[@bib27] We prespecified inclusion of both case-control and cross-sectional designs, with both population-based samples and other sampling methods. We included association studies testing for any genetic polymorphism at the nucleotide level, including single-nucleotide polymorphisms (SNPs), deletions, duplications, and copy-number variants, but excluded larger microscopic variants at the karyotype level.

There are no gold standard diagnostic methods for either stress urinary incontinence (SUI) or other LUTS, as these are largely subjective symptomatic diagnoses. For POP, validated staging systems, including POP Quantification, have been widely used, but again there is no universally accepted criterion for diagnosis. We therefore expected to accept diagnostic criteria for LUTS and prolapse as specified within each study. In view of heterogeneity in definitions across studies, we tested for heterogeneity between studies with different criteria in different settings. We accepted definitions based on symptom questionnaires, clinical examination, urodynamics, or other validated assessments. We considered the population of interest as women aged ≥18 years.

Search strategy {#sec1.2}
---------------

We combined searches from PubMed, HuGE Navigator, and an extensive selection of genetic, urological, and urogynecological conference reports. We searched PubMed up to May 1, 2014, without language restrictions, using a combination of genetic and phenotype key words and Medical Subject Headings (MeSH) terms: *(polymorphism OR SNP OR CNV OR "copy number variation" OR mutation OR genetic OR chromosome OR VNTR OR InDel OR microsatellite) AND (nocturia OR LUTS OR incontinence OR urgency OR "overactive bladder" OR prolapse OR "Lower Urinary Tract Symptoms"\[Mesh\] OR "Urinary Incontinence"\[MeSH\] OR "enuresis"\[Mesh\] OR "Pelvic Organ Prolapse"\[MeSH\]) NOT mitral NOT carcinoma\[Title\] NOT cancer\[Title\] NOT (animals\[mh\] NOT humans\[mh\])*.

We searched HuGE Navigator, also through to May 1, 2014, using the following phenotype indexing terms: *("urination disorders" OR "urinary incontinence" OR "pelvic organ prolapse")*.

In addition we searched conference abstracts for annual meetings of the American Society of Human Genetics, American Urological Association, American Urogynecologic Society, European Association of Urology, European Society of Human Genetics, International Continence Society, International Urogynecological Association, and Society of Gynecologic Surgeons 2005 through 2013.

Screening and data extraction {#sec1.3}
-----------------------------

We developed standardized data forms for this study, and conducted pilot screening and data extraction training exercises to achieve a high level of consensus between reviewers. All screening and data extraction was then performed independently and in duplicate by methodologically trained reviewers. Reviewers screened study reports by first screening titles and abstracts to select papers for full-text assessment, then screening full-text papers to confirm eligibility of the articles. Screening discrepancies were resolved by adjudication. We hand searched reference lists of all included articles, applying the same standardized screening process. When \>1 report was identified for the same association in the same study population, we included the publication with the largest sample size.

We contacted study authors by email, with a reminder after 1 month, for clarifications, additional information about methodology, and additional subgroup analyses where necessary. Data extracted included information on the setting for each study, details of the sampling strategy and sampled populations (age, parity, ethnic/racial composition, and body mass index), the overall sample size and proportion genotyped, the outcome assessments used and phenotypic definitions, the genotyping method employed, and the genotyping quality control applied. Where possible we extracted or requested from authors full genotype frequencies among both cases and controls.

Statistical analysis and risk of bias assessments {#sec1.4}
-------------------------------------------------

For polymorphisms assessed in ≥2 studies for the same phenotype assessed with similar case definitions, we conducted fixed or random effects metaanalyses as appropriate using the Metan[@bib28] package (Stata 12.1; StataCorp, College Station, TX). In all cases, we worked from genotype or allele frequencies, rather than using precalculated effect sizes. We did not pool data from studies with mixed male and female samples, unless results stratified by sex were available. We did not pool data from studies with composite case definitions (ie, any urinary incontinence) with those with simple case definitions (ie, SUI). In the absence of a clear rationale supporting any specific model of inheritance, we used the allelic association test/codominant models of inheritance for all polymorphisms. We assessed the credibility of pooled associations using the interim Venice criteria[@bib29] ([Appendix](#appsec1){ref-type="sec"}; [Supplementary Figure](#appsec1){ref-type="sec"}). We used the I^2^ statistic as a measure of between study heterogeneity. We recalculated the power of each study, and retested for departure from Hardy-Weinberg equilibrium. We made assessments of risk of bias in phenotype definitions, genotyping, and population stratification. We used the Harbord test of funnel plot asymmetry, and the significance chasing bias test[@bib30] to investigate possible reporting biases. Reporting of this review complies with recommendations both of the HuGE Handbook, and the PRISMA statement.[@bib31; @bib32]

Results {#sec2}
=======

Search outcomes {#sec2.1}
---------------

We screened 889 abstracts, and retrieved 78 full texts ([Figure 1](#fig1){ref-type="fig"}). In all, 27 published studies and 7 unpublished studies provided data ([Table 1](#tbl1){ref-type="table"}) regarding polymorphisms in or near 32 different genes ([Supplementary Table 1](#appsec1){ref-type="sec"}). Most research interest has focused on variation in genes implicated in extracellular matrix organization and disassembly, with particular focus on collagen and metalloendopeptidase genes ([Supplementary Table 2](#appsec1){ref-type="sec"}). A number of studies also addressed a variety of steroid hormone receptor genes. All studies investigated POP, SUI, or overactive bladder, with no available data on other individual LUTS.

Quantitative syntheses were possible for 11 polymorphisms in or near 7 genes: beta 3 adrenoceptor (*ADRB3*); collagen, type I, alpha 1 (*COL1A1*); collagen, type 3, alpha 1 (*COL3A1*); laminin gamma 1 (*LAMC1*); matrix metalloproteinase-1 (*MMP1*); matrix metalloproteinase-3 (*MMP3*); and matrix metalloproteinase-9 (*MMP9*).

*ADRB3* {#sec2.2}
-------

Variation in the beta-3 adrenoceptor, particularly of the rs4994 SNP, also known as Trp64Arg, has been extensively investigated in association with obesity, type 2 diabetes mellitus, and other metabolic syndrome phenotypes. The beta-3 adrenoceptor is highly expressed in bladder, and mediates detrusor muscle relaxation.[@bib33] A beta-3 adrenoceptor agonist has recently been approved for treatment of overactive bladder symptoms.[@bib34; @bib35] One conference abstract,[@bib36] and 2 published papers[@bib37; @bib38] provided relevant information on the common rs4994 missense mutation, of which 2 could be included in metaanalysis. In the initial report, in a heterogeneous Japanese sample of 13 men and 31 women, with diverse urological pathologies including neurogenic bladder and benign prostatic hyperplasia, the rs4994 SNP was not associated with LUTS (odds ratio \[OR\], 1.20; 95% confidence interval \[CI\], 0.32--4.47).[@bib36] Results were not available stratified by sex, and could not be included in quantitative synthesis. Subsequent reports used larger samples of Japanese women,[@bib37] and Brazilian women[@bib38] ([Table 1](#tbl1){ref-type="table"}), and looked specifically at the overactive bladder phenotype, finding a large effect size (pooled OR, 2.46; 95% CI, 1.67--3.60) ([Figure 2](#fig2){ref-type="fig"}), with no heterogeneity. Despite a lack of information about genotyping quality control (QC), and some risk of population stratification, this large effect size confers some protection from bias, providing Venice grading BBB, or moderate epidemiological credibility ([Table 2](#tbl2){ref-type="table"}).

*COL1A1* {#sec2.3}
--------

rs1800012 also known as the Sp1-binding site polymorphism of collagen, type I, alpha 1, modifies transcription factor binding and gene expression. It has been most extensively studied in association with osteoporosis, where the minor allele is modestly associated with reduced bone mineral density and increased fracture risk.[@bib39] Collagen, type I, alpha 1 is a major structural component of the vaginal epithelium and endopelvic fascia. The available data on gene and protein expression in pelvic tissue from women with prolapse or stress incontinence are heterogeneous but suggest increased *COL1A1* expression with reduced type 1 collagen content.[@bib40] Seven studies provided data on the rs1800012 SNP in association with either POP or stress incontinence, of which 6 could be included in quantitative syntheses.

Five studies reported associations of rs1800012 with anatomical POP in Brazilian,[@bib41] Israeli,[@bib42] Polish,[@bib43] Italian,[@bib44] and Korean[@bib45] populations ([Table 1](#tbl1){ref-type="table"}). The Korean study found only the wild type GG allele among all 30 participants, and could not be included in quantitative synthesis. Despite each individual study being underpowered, the pooled effect size for the remaining 4 studies was significant (OR, 1.33; 95% CI, 1.02--1.73) ([Figure 3](#fig3){ref-type="fig"}) with low inconsistency. With limited information about genotyping QC, and a possible risk of population stratification in 2 samples,[@bib41; @bib42] we considered that bias could not be fully excluded, providing Venice grading BBB, or moderate epidemiological credibility ([Table 2](#tbl2){ref-type="table"}).

Two studies of Polish[@bib46] and Greek[@bib47] women reported associations of the same polymorphism with stress incontinence, in both cases using a combined symptomatic and objectively measured case definition. The pooled effect size was large (OR, 2.09; 95% CI, 1.35--3.22) ([Figure 3](#fig3){ref-type="fig"}) with no heterogeneity (I^2^ = 0%). There was significant deviation from Hardy-Weinberg equilibrium in one sample,[@bib46] suggesting significant potential for bias. However, exclusion of this study would not change the result. With high risk of bias the Venice grading was CBC, or weak epidemiological credibility ([Table 2](#tbl2){ref-type="table"}).

*COL3A1* {#sec2.4}
--------

A large number of mutations in collagen, type 3, alpha 1 have been associated with vascular Ehlers-Danlos syndrome. Inconsistent evidence suggests that urinary incontinence and prolapse may be prevalent among women with Ehlers-Danlos.[@bib48] Collagen, type 3 has a particular function in tissue repair, and is typically overexpressed in pelvic tissues from women with prolapse.[@bib40] We identified studies testing associations with 2 missense variants rs1800255 and rs111929073, as well as 1 synonymous SNP rs1801184. Both missense variants had been tested in 2 studies, and therefore could be combined in quantitative syntheses. Separate Taiwanese[@bib49] and Dutch[@bib50] studies found a nonsignificant pooled association between rs1800255 and anatomic prolapse (OR, 1.19; 95% CI, 0.88--1.61) ([Figure 4](#fig4){ref-type="fig"}), with no heterogeneity ([Table 2](#tbl2){ref-type="table"}).

For rs111929073, separate Korean[@bib51] and Brazilian[@bib52] samples demonstrated a nonsignificant pooled effect (OR, 0.56; 95% CI, 0.19--1.61) ([Figure 4](#fig4){ref-type="fig"}) with high heterogeneity (I^2^ = 83.7%, *P* \< .01). Case definitions were similar for the 2 studies, making this an unlikely source of heterogeneity. The primary Korean study had suggested a large protective effect of the minor allele, and the heterogeneity between studies might instead be explained by differences in populations, or a simple Proteus effect.

*LAMC1* {#sec2.5}
-------

Laminin gamma 1 is 1 of 3 kinds of laminin chain that combine to make different laminin isoforms. These extracellular matrix glycoproteins are an important constituent of basement membranes, with roles in cell adhesion and migration. *LAMC1* was initially proposed as a candidate gene for prolapse in a linkage study of 9 individuals from a family affected by early-onset severe prolapse.[@bib53] We identified 3 further studies all from the United States that attempted to replicate this initial report of an association with rs10911193,[@bib54; @bib55; @bib56] with all 3 including testing of additional SNPs ([Table 1](#tbl1){ref-type="table"}).

All 3 individual studies found no association for rs10911193, with a nonsignificant pooled effect (OR, 1.13; 95% CI, 0.83--1.53) ([Figure 5](#fig5){ref-type="fig"}) and no heterogeneity. There was no evidence of small study bias or publication bias. Genotyping QC was generally well documented for these studies, and population stratification appropriately accounted for. Two of the studies[@bib54; @bib55] provided further data on rs20563 and rs20558, 2 missense SNPs in near perfect linkage disequilibrium, but again with nonsignificant pooled effects (both OR, 1.12; 95% CI, 0.92--1.38) ([Figure 5](#fig5){ref-type="fig"}) and no heterogeneity.

*MMP1* {#sec2.6}
------

Matrix metalloproteinase-1, also known as interstitial collagenase, is one of a number of enzymes that cleave collagen type 1. The *MMP1* gene is up-regulated in pelvic tissues of women with prolapse.[@bib40] Common variants of this gene have been extensively studied in association with chronic obstructive pulmonary disease,[@bib57] cardiovascular disease,[@bib58] and a number of cancers including of lung, colon, and breast. We identified 2 unpublished studies from the United States,[@bib59; @bib60] and 2 published studies of Polish[@bib61; @bib62] and Italian[@bib44] samples assessing associations between MMP1 variants and stress incontinence or prolapse. Of these, 2 studies reported on rs1799750 in association with prolapse,[@bib44; @bib61] with a nonsignificant pooled effect (OR, 0.97; 95% CI, 0.76--1.25) ([Figure 6](#fig6){ref-type="fig"}) with no heterogeneity. One of the 2 studies included demonstrated marked deviation from Hardy-Weinberg equilibrium, and exclusion of this study would however leave a single eligible study with a nonsignificant association (OR, 0.88; 95% CI, 0.60--1.27).[@bib44] For the 2 studies testing associations with SUI,[@bib60; @bib61] the pooled effect was again nonsignificant (OR, 0.87; 95% CI, 0.63--1.20), with no heterogeneity.

*MMP3* {#sec2.7}
------

Matrix metalloproteinase-3, also known as stromelysin-1, is an enzyme that degrades a number of extracellular matrix components including collagen type 3 and elastin. Similarly to *MMP1*, its common variants have received most research attention in association with cardiovascular disease,[@bib58] and a number of cancers. We identified 2 studies again of women of European descent,[@bib44; @bib61; @bib62] both testing associations of rs3025058, known as the 5A/6A promoter InDel, with prolapse. The pooled effect was again nonsignificant (OR, 1.11; 95% CI, 0.86--1.43) ([Figure 7](#fig7){ref-type="fig"}) with no heterogeneity.

*MMP9* {#sec2.8}
------

Matrix metalloproteinase-9, also known as 92-kDa type IV collagenase, degrades collagen type 4 and type 5. Some evidence suggests increased activation of MMP9 in pelvic tissues from women with prolapse.[@bib63] Like *MMP1* and *MMP3*, its common polymorphisms have been linked to chronic obstructive pulmonary disease,[@bib57] cardiovascular disease,[@bib58] and some cancers. We identified 4 studies of Italian,[@bib44] Taiwanese,[@bib64] and white US[@bib63; @bib65] samples, assessing 10 different polymorphisms in association with prolapse. Three studies contributed to a metaanalysis of the rs17576 missense polymorphism. The pooled effect was nonsignificant (OR, 1.02; 95% CI, 0.81--1.28) ([Figure 8](#fig8){ref-type="fig"}) but with significant heterogeneity (I^2^ = 68.9%, *P* = .04). Case definitions were similar for the 3 studies, making this an unlikely source of heterogeneity. All studies demonstrated Hardy-Weinberg equilibrium, and we judged a low risk of population stratification. The single study among Asian women[@bib64] suggested a narrowly significant effect (OR, 0.62; 95% CI, 0.40--0.98), while subgroup analysis of the 2 white US samples showed no pooled effect (OR, 1.22; 95% CI, 0.93--1.60). Two studies contributed to metaanalysis of rs3918242, with a nonsignificant effect (OR, 1.25; 95% CI, 0.83--1.89) ([Figure 8](#fig8){ref-type="fig"}) and no heterogeneity.

Publication bias and selective analysis {#sec2.9}
---------------------------------------

Each metaanalysis included at most 4 studies or subgroups, providing low power for conventional measures of funnel plot asymmetry. The Harbord test demonstrated no evidence of small study bias or publication bias (all *P* \> .1). We applied the significance chasing bias test,[@bib30] to look for further evidence of publication bias or selective outcome reporting. This exploratory test is used to detect an excess of significant results, either within a single metaanalysis, or in a whole domain of research. In common with other tests of publication bias, *P* \< .1 is usually taken as the threshold for significance. We applied the test across each of the 13 metaanalyses conducted individually, and for the 13 considered together as 1 domain. Given the power of the individual studies to detect the observed pooled effect sizes in each metaanalysis, across the domain as a whole we expected 6.61 statistically significant studies, and observed 7 significant studies in our own prespecified reanalyses using the allelic test (*P* = .87). However, primary publications applied a variety of analytic techniques, and from the set of studies included in metaanalysis we observed 11 studies reporting statistically significant results in their own analyses (*P* = .14), typically using alternative models of inheritance. These findings are suggestive primarily of selective analysis, rather than publication bias. Individual metaanalyses again provided limited power for this test, but possible bias was most apparent in the quantitative synthesis of association of prolapse with the rs17576 SNP of MMP9 (*P* = .11).

Genes and/or polymorphisms reported in a single study {#sec2.10}
-----------------------------------------------------

Among the included studies, some had assessed associations with polymorphisms for which no replication has been reported. Statistically significant associations have been suggested between prolapse and the rs2228480 polymorphism of *ESR1*, the estrogen receptor alpha[@bib66]; between prolapse and certain haplotypes of *ESR2*, the estrogen receptor beta[@bib67]; between prolapse and the rs484389 polymorphism of *PGR*, the progesterone receptor[@bib68]; between prolapse and the rs10478694 polymorphism of *EDN1*, endothelin 1[@bib69]; between incontinence and the CAG copy number variant of *AR*, the androgen receptor[@bib70]; between incontinence and the rs6313 polymorphism of *HTR2A*, the serotonin 2A receptor[@bib71]; between stress incontinence and both the rs2165241 and rs1048661 variants of *LOX-L1*, lysyloxidaselike-1[@bib72]; between the rs1136410 polymorphism of poly-ADP ribose polymerase (*PARP*)[@bib73] and prolapse; and finally between the rs1695 polymorphism of glutathione S-transferase pi (*GSTP1*) and prolapse.[@bib74] We found only 1 published study reporting entirely nonsignificant results,[@bib75] further suggesting a high probability of selective outcome reporting or publication bias for this field of study as a whole. Following the Venice recommendations,[@bib28] we a priori assigned all nominally significant but unreplicated associations weak epidemiological credibility. Three genome-wide association studies (GWAS) have now been reported for incontinence or prolapse.[@bib76; @bib77; @bib78] Of note, none of these suggested candidates for prolapse or incontinence, including both those from single studies, as well as those included in metaanalyses, were identified in these genome-wide analyses. Across the 3 GWAS, SNPs at 9 independent loci have reached genome-wide significance (*P* \< 5 × 10^-8^) ([Table 1](#tbl1){ref-type="table"}) in discovery cohorts, although replication of these candidate loci has not been demonstrated.

Comment {#sec3}
=======

Strengths and limitations {#sec3.1}
-------------------------

The strengths of this review include a comprehensive search of both published and unpublished studies, applying explicit criteria to potentially eligible studies, and employing standardized, piloted data forms for data collection, guided by written instructions, and an unbiased assessment and synthesis of reported associations. We followed a prespecified data analysis plan, and contacted authors for clarifications and additional data.

Among the challenges faced in this review was the inclusion of studies with varying diagnostic criteria. There may be considerable disparity between symptomatic and objective findings for both LUTS and prolapse, and despite long-standing efforts for standardization[@bib2] diagnostic criteria are not widely agreed upon. Despite this caution, we found that the literature had used largely concordant definitions. From the prolapse studies, 2 studies had used a prolapse case definition based on need for surgical treatment, but all others used an accepted anatomic staging system, typically POP Quantification. There was also little variation in cutoffs for significant prolapse, with almost all studies considering prolapse stage 0 or stage 1 as normal/control. Both overactive bladder studies included in metaanalysis used a combination of self-reported symptoms, with 3-day bladder diary for diagnosis. Similarly both SUI studies included in metaanalysis used a combination of cystometry and pad testing for diagnosis. This is reflected in a lack of heterogeneity in most metaanalyses. Regardless of the presence of statistical heterogeneity, there remains potential for bias toward the null from heterogeneity in case definitions.

It is evident that overactive bladder in particular may have multiple underlying causes,[@bib79; @bib80] and these syntheses may therefore include participants with diverse underlying etiologies for their symptoms. The largest metaanalyses possible still include \<1000 participants in total, and therefore provide adequate power only for associations with large effect size (approximately OR, ≤0.6 or OR, ≥1.8). It is both likely that smaller effect sizes have been missed in these syntheses, and highly probable that polymorphisms with larger effect sizes are still to be discovered.

Future work {#sec3.2}
-----------

Future advances are likely within the context of GWAS using large-scale population-based cohorts phenotyped for these conditions. The discovery of further causative variants should both help to explain the complex pathophysiology of these conditions, and provide potentially a route to effective prevention and treatment.

Conclusions {#sec3.3}
-----------

Family and twin studies have provided convincing evidence for genetic predisposition to incontinence, prolapse, and overactive bladder, with genetic variation contributing up to half of population phenotypic variability. These metaanalyses provide moderate epidemiological credibility for associations of variation in *ADRB3* with overactive bladder, and *COL1A1* with prolapse. As for all complex diseases, these 2 currently identified polymorphisms explain a tiny fraction of that phenotypic variation. The widespread availability of direct-to-consumer testing means that some patients may present with questions about the implications of these polymorphisms. However, testing for any of these SNPs cannot be recommended based on current evidence. Nevertheless, clinicians and researchers should be aware of the putative risks associated with these SNPs, and the uncertainty regarding potential biases in the primary studies. In the future, genetic counseling may play one part of advice about risks of mode of delivery, and may help target women for primary or secondary prevention. Currently, clinicians should continue to use a family history of prolapse or incontinence as a simple marker of future risk, with clearly documented interactions with modifiable risk factors such as vaginal childbirth and obesity.

Appendix {#appsec1}
========

Supplementary FigureSummary of interim Venice guideline ratings of credibility of genetic associationsStrong credibility for association requires AAA rating. Any B rating confers maximum moderate credibility, while any C rating confers weak credibility.*Cartwright. Genetic association studies of LUTS and POP. Am J Obstet Gynecol 2015*.Adapted and abridged from Ioannidis et al.[@bib29]Supplementary Table 1Functional annotation of investigated genesOfficial gene symbolGene name(s)No. of studies includedMolecular function(s)*ADRA1A*Adrenergic, alpha-1A-, receptor1Adrenoceptor activity\
Alpha-adrenergic receptor activity\
Alpha1-adrenergic receptor activity\
Amine receptor activity*ADRB3*Adrenergic, beta-3-, receptor3Adrenoceptor activity\
Beta-adrenergic receptor activity\
Amine receptor activity\
Beta-3-adrenergic receptor activity\
Adrenergic receptor binding\
Beta-3 adrenergic receptor binding\
Identical protein binding\
Protein homodimerization activity\
Amine binding\
Alcohol binding\
Protein dimerization activity\
Epinephrine binding\
Norepinephrine binding*AR*Androgen receptor1DNA binding\
Transcription factor activity\
Steroid hormone receptor activity\
Ligand-dependent nuclear receptor activity\
Androgen receptor activity\
Steroid binding\
Androgen binding\
Zinc ion binding\
Lipid binding\
Transcription activator activity\
Transcription regulator activity\
Hormone binding\
Ion binding\
Cation binding\
Sequence-specific DNA binding\
Metal ion binding\
Transition metal ion binding\
Protein dimerization activity*COL1A1*Collagen, type I, alpha 17Structural molecule activity\
Extracellular matrix structural constituent\
Growth factor binding\
Identical protein binding\
Platelet-derived growth factor binding,*COL3A1*Collagen, type III, alpha 14Integrin binding\
Structural molecule activity\
Extracellular matrix structural constituent\
Growth factor binding\
Protein complex binding\
SMAD binding\
Platelet-derived growth factor binding*COL18A1*Collagen, type XVIII, alpha 11Structural molecule activity\
Extracellular matrix structural constituent\
Zinc ion binding\
Ion binding\
Cation binding\
Metal ion binding\
Transition metal ion binding*CPE*Carboxypeptidase E1Metallocarboxypeptidase activity\
Zinc ion binding*CYP17A1*Cytochrome P450, family 17, subfamily A, polypeptide 11Steroid 17-alpha-monooxygenase activity\
Iron ion binding\
Steroid hydroxylase activity\
Electron carrier activity\
Oxygen binding\
Heme binding\
Ion binding\
Cation binding\
Metal ion binding\
Tetrapyrrole binding\
Transition metal ion binding*CYP19A1*Cytochrome P450, family 19, subfamily A, polypeptide 11Iron ion binding\
Electron carrier activity\
Oxidoreductase activity\
Oxygen binding\
Heme binding\
Ion binding\
Cation binding\
Metal ion binding\
Tetrapyrrole binding\
Transition metal ion binding\
Aromatase activity*EDN1*Endothelin 11Hormone activity\
Bombesin receptor binding\
Endothelin A receptor binding\
Endothelin B receptor binding*ESR1*Estrogen receptor 11DNA binding\
Transcription factor activity\
Steroid hormone receptor activity\
Ligand-dependent nuclear receptor activity\
Steroid binding\
Zinc ion binding\
Lipid binding\
Promoter binding\
Nitric-oxide synthase regulator activity\
Estrogen receptor activity\
Transcription regulator activity\
Estrogen response element binding\
Hormone binding\
Ion binding\
Cation binding\
Sequence-specific DNA binding\
Metal ion binding transition\
Metal ion binding\
Protein N-terminus binding*ESR2*Estrogen receptor 2 (ER beta)1DNA binding\
Transcription factor activity\
Steroid hormone receptor activity\
Transcription cofactor activity\
Transcription coactivator activity\
Ligand-dependent nuclear receptor activity\
Steroid binding transcription factor binding\
Zinc ion binding\
Lipid binding\
Transcription activator activity\
Estrogen receptor activity\
Transcription regulator activity\
Receptor regulator activity\
Receptor inhibitor activity\
Hormone binding\
Ion binding\
Cation binding\
Sequence-specific DNA binding\
Metal ion binding\
Transition metal ion binding\
Receptor antagonist activity*GSTM1*Glutathione S-transferase mu 11Glutathione transferase activity*GSTP1*Glutathione S-transferase pi 11Glutathione transferase activity*GSTT1*Glutathione S-transferase theta 11Glutathione transferase activity*HTR2A*5-Hydroxytryptamine (serotonin) receptor 2A1Serotonin receptor activity\
Amine receptor activity\
Protein complex binding\
Amine binding\
Serotonin binding*LAMC1*Laminin, gamma 1 (formerly LAMB2)3Structural molecule activity\
Extracellular matrix structural constituent,*LOXL1*Lysyl oxidase-like 13Copper ion binding\
Oxidoreductase activity\
Ion binding\
Cation binding\
Metal ion binding\
Transition metal ion binding*MMP1*Matrix metallopeptidase 1 (interstitial collagenase)5Endopeptidase activity\
Metalloendopeptidase activity\
Calcium ion binding\
Peptidase activity\
Metallopeptidase activity\
Zinc ion binding\
Ion binding\
Cation binding\
Metal ion binding\
Transition metal ion binding\
Peptidase activity\
Acting on L-amino acid peptides*MMP10*Matrix metallopeptidase 10 (stromelysin 2)1Endopeptidase activity\
Metalloendopeptidase activity\
Calcium ion binding\
Peptidase activity\
Metallopeptidase activity\
Zinc ion binding\
Ion binding\
Cation binding\
Metal ion binding\
Transition metal ion binding\
Peptidase activity\
Acting on L-amino acid peptides*MMP11*Matrix metallopeptidase 11 (stromelysin 3)1Endopeptidase activity\
Metalloendopeptidase activity\
Calcium ion binding\
Peptidase activity\
Metallopeptidase activity\
Zinc ion binding\
Ion binding\
Cation binding\
Metal ion binding\
Transition metal ion binding\
Peptidase activity\
Acting on L-amino acid peptides*MMP2*Matrix metallopeptidase 2 (gelatinase A, 72-kDa gelatinase, 72-kDa type IV collagenase)1Endopeptidase activity\
Metalloendopeptidase activity\
Calcium ion binding\
Peptidase activity\
Metallopeptidase activity\
Zinc ion binding\
Ion binding\
Cation binding\
Metal ion binding\
Transition metal ion binding\
Peptidase activity\
Acting on L-amino acid peptides*MMP3*Matrix metallopeptidase 3 (stromelysin 1, progelatinase)3Endopeptidase activity\
Metalloendopeptidase activity\
Calcium ion binding\
Peptidase activity\
Metallopeptidase activity\
Zinc ion binding\
Ion binding\
Cation binding\
Metal ion binding\
Transition metal ion binding\
Peptidase activity\
Acting on L-amino acid peptides*MMP8*Matrix metallopeptidase 8 (neutrophil collagenase)1Endopeptidase activity\
Metalloendopeptidase activity\
Calcium ion binding\
Peptidase activity\
Metallopeptidase activity\
Zinc ion binding\
Ion binding\
Cation binding\
Metal ion binding\
Transition metal ion binding\
Peptidase activity\
Acting on L-amino acid peptides*MMP9*Matrix metallopeptidase 9 (gelatinase B, 92-kDa gelatinase, 92-kDa type IV collagenase)4Endopeptidase activity\
Metalloendopeptidase activity\
Calcium ion binding\
Peptidase activity\
Metallopeptidase activity\
Zinc ion binding\
Ion binding\
Cation binding\
Metal ion binding\
Transition metal ion binding\
Peptidase activity\
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![Flowchart outlining literature search and article evaluation process\
^a^ American Society of Human Genetics, American Urological Association, American Urogynecologic Society, European Association of Urology, European Society of Human Genetics, International Continence Society, International Urogynecological Association, and Society of Gynecologic Surgeons abstracts 2005 through 2014, using online search interfaces and/or full text search of abstract book PDFs; ^b^ Includes studies enrolling only men (n = 122), enrolling only children (n = 2), narrative reviews or letters (n = 12), inapplicable phenotype (n = 2), and other study designs including pharmacogenetic studies, gene expression studies, or methylation studies (n = 8); ^c^ Authors contacted by email for additional data from 18 studies.\
*Cartwright. Genetic association studies of LUTS and POP. Am J Obstet Gynecol 2015*.](gr1){#fig1}

![Forest plot of rs4994 SNP of ADRB3 and overactive bladder\
Forest plot of studies[@bib37; @bib38] reporting associations between rs4994 single-nucleotide polymorphism (SNP)\* of beta 3 adrenoceptor gene and overactive bladder. \*RefSNP alleles C/T. Plot presented as risk associated with minor allele C.\
*CI*, confidence interval; *OR*, odds ratio.\
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![Forest plot of studies of rs1800013 SNP of COL1A1\
Forest plot of studies[@bib41; @bib42; @bib43; @bib44; @bib46; @bib47] reporting associations between rs1800012 single-nucleotide polymorphism (SNP)\* of collagen type 1 alpha 1 gene and either stress urinary incontinence (SUI) or pelvic organ prolapse (POP). \*RefSNP alleles G/T. Plot presented as risk associated with minor allele T.\
*CI*, confidence interval; *OR*, odds ratio.\
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![Forest plot of COL3A1 SNPs and prolapse\
Forest plot of studies[@bib49; @bib50; @bib51; @bib52] reporting associations between rs1800255\* and rs111929073\* single-nucleotide polymorphisms (SNPs) of collagen type 3, alpha 1 gene and pelvic organ prolapse with either fixed or random effects models\*\*. \*For both SNPs RefSNP alleles A/G. Plot presented as risk associated with minor allele A. \*\*Mantel-Haenszel fixed effects model (M-H)/DerSimonian and Laird random effects model (D+L).\
*CI*, confidence interval; *OR*, odds ratio.\
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![Forest plot of LAMC1 SNPs and prolapse\
Forest plot of studies[@bib54; @bib55; @bib56] reporting associations among rs10911193, rs20563, and rs20558 single-nucleotide polymorphisms (SNPs) of laminin gamma 1 gene and pelvic organ prolapse. \*African American subsample. \*\*White subsample. rs10911193 RefSNP alleles C/T. Plot presented as risk associated with minor allele T. rs20563 RefSNP alleles A/G. Plot presented as risk associated with minor allele A. rs20558 RefSNP alleles C/T. Plot presented as risk associated with minor allele C.\
*CI*, confidence interval; *OR*, odds ratio.\
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![Forest plot of rs1799750 SNP of MMP1\
Forest plot of studies[@bib44; @bib60; @bib61] reporting associations between rs1799750\* single-nucleotide polymorphism (SNP) of matrix metalloproteinase 1 (MMP1) gene and either stress urinary incontinence (SUI) or pelvic organ prolapse (POP) with either fixed or random effects models. ∗RefSNP Alleles -/G. Plot presented as risk associated with minor deletion allele.\
*CI*, confidence interval; *OR*, odds ratio.\
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![Forest plot of rs3025058 SNP of MMP3 and prolapse\
Forest plot of studies[@bib6; @bib44] reporting associations between rs3025058\* single-nucleotide polymorphism (SNP) of matrix metalloproteinase 3 gene and pelvic organ prolapse. \*RefSNP Alleles -/T. Plot presented as risk associated with minor deletion allele.\
*CI*, confidence interval; *OR*, odds ratio.\
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![Forest plot of MM9 SNPs and prolapse\
Forest plot of studies[@bib44; @bib63; @bib64; @bib65] reporting associations between rs3918242\* and rs17576\*\* single-nucleotide polymorphisms (SNPs) of matrix metalloproteinase 9 gene and pelvic organ prolapse with either fixed or random effects models⌘. \*rs3918242 RefSNP alleles C/T. Plot presented as risk associated with minor allele T. \*\*rs17576 RefSNP alleles A/G. Plot presented as risk associated with minor allele A. ⌘Mantel-Haenszel fixed effects model (M-H)/DerSimonian and Laird random effects model (D+L).\
*CI*, confidence interval; *OR*, odds ratio.\
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###### 

Included studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                         Journal and year                        Country                          Descent, ethnicity, race[a](#tbl1fna){ref-type="table-fn"}   Gene symbols(s)                            Polymorphism(s) dbSNP ID   Case definition                                                            Control definition                                            Cases genotyped, n                Controls genotyped, n
  ----------------------------- --------------------------------------- -------------------------------- ------------------------------------------------------------ ------------------------------------------ -------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------- --------------------------------- -----------------------
  Allen-Brady et al[@bib76]     Obstet Gynecol 2011                     United States, The Netherlands   White and Northern European descent                          *LINC0108*^*b*^\                           rs1455311\                 Surgically treated/recurrent POP with family history                       Population controls                                           191                               3036
                                                                                                                                                                      *ZFAT*\                                    rs1036819\                                                                                                                                                                                            
                                                                                                                                                                      Intergenic\                                rs430794\                                                                                                                                                                                             
                                                                                                                                                                      Intergenic\                                rs8027714\                                                                                                                                                                                            
                                                                                                                                                                      Intergenic\                                rs1810636\                                                                                                                                                                                            
                                                                                                                                                                      *COL18A1*                                  rs2236479                                                                                                                                                                                             

  Campeau et al[@bib59]         Neurourol Urodyn 2011 (ICS abstract)    United States                    Not stated                                                   *MMP1*                                     rs1144393\                 Surgically treated POP                                                     Hospital controls "without POP"                               63                                93
                                                                                                                                                                                                                 rs498186\                                                                                                                                                                                             
                                                                                                                                                                                                                 rs473509                                                                                                                                                                                              

  Chen et al[@bib55]            Am J Obstet Gynecol 2010                United States                    African American and Caucasian                               *LAMC1*                                    rs10911193\                POP stage \>II                                                             POP stage \<II                                                165                               246
                                                                                                                                                                                                                 rs20563\                                                                                                                                                                                              
                                                                                                                                                                                                                 rs20558                                                                                                                                                                                               

  Chen et al[@bib66]            Int Urogynecol J 2008                   Taiwan                           Taiwanese                                                    *ESR1*                                     rs17847075\                POPQ ≥2                                                                    POPQ \<2                                                      88                                153
                                                                                                                                                                                                                 rs2207647\                                                                                                                                                                                            
                                                                                                                                                                                                                 rs2234693\                                                                                                                                                                                            
                                                                                                                                                                                                                 rs3798577\                                                                                                                                                                                            
                                                                                                                                                                                                                 rs2228480                                                                                                                                                                                             

  Chen et al[@bib68]            Acta Obstet Gynecol 2009                Taiwan                           Taiwanese                                                    PGR                                        rs500760\                  POPQ ≥2                                                                    POPQ \<2                                                      87                                150
                                                                                                                                                                                                                 rs484389                                                                                                                                                                                              

  Chen et al[@bib78]            Am Soc Hum Genet 2013                   United States                    African American and Hispanic American                       *PRCP*^*b*^                                rs2086297                  Symptomatic SUI                                                            No SUI                                                        ≈3343                             ≈8183

  Chen et al[@bib66]            Int Urogynecol J 2008                   Taiwan                           Taiwanese                                                    *COL3A1*                                   rs1800255\                 POPQ ≥2                                                                    POPQ \<2                                                      84                                147
                                                                                                                                                                                                                 rs1801184                                                                                                                                                                                             

  Chen et al[@bib64]            Eur J Obstet Gynecol 2010               Taiwan                           Taiwanese                                                    *MMP9*                                     rs3918242\                 POPQ ≥2                                                                    POPQ \<2                                                      92                                152
                                                                                                                                                                                                                 rs17576\                                                                                                                                                                                              
                                                                                                                                                                                                                 rs2250889                                                                                                                                                                                             

  Chen et al[@bib67]            Eur J Obstet Gynecol 2008               Taiwan                           Taiwanese                                                    *ESR2*                                     rs2987983\                 POPQ ≥2                                                                    POPQ \<2                                                      69                                141
                                                                                                                                                                                                                 rs1271572\                                                                                                                                                                                            
                                                                                                                                                                                                                 rs944459\                                                                                                                                                                                             
                                                                                                                                                                                                                 rs1256049\                                                                                                                                                                                            
                                                                                                                                                                                                                 rs1255998                                                                                                                                                                                             

  Cho et al[@bib45]             Yonsei Med J 2009                       Korea                            Korean                                                       *COL1A1*                                   rs1800012                  Surgically treated POPQ ≥3                                                 POPQ = 0                                                      15                                15

  Choy et al[@bib69]            ICS abstract 2007                       Hong Kong                        Chinese                                                      *EDN1*                                     rs5370\                    POPQ ≥2                                                                    Hospital "normal'' controls and HapMap Han Chinese controls   60 (rs5370) and 67 (rs10478694)   210
                                                                                                                                                                                                                 rs10478694                                                                                                                                                                                            

  Cornu et al[@bib70]           World J Urol 2011                       France                           Caucasian                                                    *ESR1*\                                    rs2234693\                 Treated for UI (30 UUI, 107 SUI)                                           No UI or OAB                                                  121                               66
                                                                                                                                                                      *CYP17A1*\                                 rs743572\                                                                                                                                                                                             
                                                                                                                                                                      *CYP19A1*\                                 rs60271534\                                                                                                                                                                                           
                                                                                                                                                                      *AR*                                       CAG repeat                                                                                                                                                                                            

  Feiner et al[@bib42]          Int Urogynecol J 2009                   Israel                           Caucasian or Ashkenazi-Jewish                                *COL1a1*                                   rs1800012                  POPQ ≥3                                                                    POPQ \<2                                                      36                                36

  Ferrari et al[@bib44]         Arch Gynecol Obstet 2012                Italy                            Italian                                                      *COL1a1*\                                  rs1800012\                 POPQ ≥2                                                                    POPQ \<2                                                      137                               96
                                                                                                                                                                      *MMP9*\                                    rs3918242\                                                                                                                                                                                            
                                                                                                                                                                      *MMP1*\                                    rs1799750\                                                                                                                                                                                            
                                                                                                                                                                      *MMP3*                                     rs3025058                                                                                                                                                                                             

  Ferreira et al[@bib38]        Am J Obstet Gynecol 2011                Brazil                           White or nonwhite                                            *ADRB3*                                    rs4994                     Symptomatic OAB without severe SUI                                         No LUTS                                                       49                                169

  Ferrell et al[@bib75]         Reprod Sci 2009                         United States                    African American or Caucasian                                *LOXL1*                                    rs16958477                 POP stage ≥II                                                              POP stage \<II                                                137                               130

  Fu et al[@bib56]              J Urol 2009 (AUA abstract)              United States                    Not stated                                                   *LAMC1*\                                   rs10911193                 POP stage ≥III                                                             No POP or UI                                                  61                                33
                                                                                                                                                                      *LOXL1*                                                                                                                                                                                                                                          

  Honda et al[@bib37]           Neurourol Urodyn 2014                   Japan                            Japanese                                                     *ADRb3*                                    rs4994                     Symptomatic OAB                                                            No OAB                                                        100                               101

  Jeon et al[@bib51]            J Urol 2009                             Korea                            Korean                                                       *COL3a1*                                   rs111929073                POPQ ≥2                                                                    POPQ \<2 and no SUI                                           36                                36

  Kim et al[@bib74]             Eur J Obstet Gynecol Reprod Biol 2014   Korea                            Korean                                                       *GSTM1*\                                   Null\                      POPQ ≥3                                                                    POPQ \<2                                                      189                               156
                                                                                                                                                                      *GSTT1*\                                   Null\                                                                                                                                                                                                 
                                                                                                                                                                      *GSTP1*                                    rs1695                                                                                                                                                                                                

  Kim et al[@bib73]             Menopause 2014                          Korea                            Korean                                                       *PARP1*                                    rs1136410                  POPQ ≥3                                                                    POPQ \<2                                                      185                               155

  Lince et al[@bib50]           Int Urogynecol J 2014                   The Netherlands                  ≈99% Dutch                                                   *COL3a1*                                   rs1800255                  POPQ ≥2                                                                    POPQ \<2                                                      272                               82

  Martins et al[@bib52]         Neurourol Urodyn 2011                   Brazil                           White or nonwhite                                            *COL3a1*                                   rs111929073                POP stage ≥III                                                             POP stage \<II                                                107                               209

  Noronha et al[@bib71]         J Investig Med 2010                     Brazil                           Predominant European/white                                   *HTR2A*                                    rs6313                     Symptomatic UI                                                             Self-reported continent women, and population controls        68                                849

  Ozbek et al[@bib72]           J Obstet Gynaecol Res 2013              Turkey                           Caucasian                                                    *LOXL1*                                    rs2165241\                 Symptomatic SUI                                                            No UI                                                         93                                75
                                                                                                                                                                                                                 rs3825942\                                                                                                                                                                                            
                                                                                                                                                                                                                 rs1048661                                                                                                                                                                                             

  Rodrigues et al[@bib41]       Int Urogynecol J 2008                   Brazil                           White or nonwhite                                            *COL1a1*                                   rs1800012                  POP stage ≥III                                                             POP stage \<II and no SUI                                     107                               209

  Romero and Jamison[@bib65]    J Pelv Med Surg 2008                    United States                    White                                                        *MMP1*\                                    rs2071230\                 POPQ ≥3                                                                    POPQ \<2 and no UI                                            45                                38
                                                                                                                                                                      *MMP2*\                                    rs7201\                                                                                                                                                                                               
                                                                                                                                                                      *MMP3*\                                    rs679620\                                                                                                                                                                                             
                                                                                                                                                                      *MMP8*\                                    rs35866072\                                                                                                                                                                                           
                                                                                                                                                                      *MMP9*\                                    rs17576\                                                                                                                                                                                              
                                                                                                                                                                      *MMP10*\                                   rs17435959\                                                                                                                                                                                           
                                                                                                                                                                      *MMP11*\                                   rs738789\                                                                                                                                                                                             
                                                                                                                                                                      *TIMP1*\                                   rs4898\                                                                                                                                                                                               
                                                                                                                                                                      *TIMP3*                                    rs2016293                                                                                                                                                                                             

  Sioutis et al[@bib47]         Int Urogynecol J 2011                   Greece                           Greek                                                        *COL1a1*                                   rs1800012                  SUI confirmed with urodynamics and positive pad test, and postmenopausal   Healthy postmenopausal                                        45                                45

  Skorupski[@bib43]             Int Urogynecol J 2009 (IUGA abstract)   Poland                           Polish                                                       *COL1a1*                                   rs1800012                  POPQ ≥2                                                                    POPQ \<2 and no UI                                            120                               97

  Skorupski et al[@bib46]       Am J Obstet Gynecol 2006                Poland                           Polish                                                       *COL1a1*                                   rs1800012                  SUI confirmed with urodynamics and positive pad test                       POPQ \<2 and no UI                                            50                                50

  Skorupski et al[@bib61]       Ginekol Polska 2010                     Poland                           Polish                                                       *MMP1*\                                    rs1799750\                 POPQ ≥2                                                                    POPQ \<2                                                      132                               133
                                                                                                                                                                      *MMP3*                                     rs3025058                                                                                                                                                                                             

  Takeda et al[@bib36]          ICS Abstract 2002                       Japan                            Japanese                                                     *ADRb3*\                                   rs4994\                    Any LUTS (includes mixed group of women and men)                           No LUTS                                                       27                                17
                                                                                                                                                                      *ADRA1A*                                   rs1048101                                                                                                                                                                                             

  Velez Edwards et al[@bib77]   Am Soc Hum Gen 2013                     United States                    African American and Hispanic American                       *CPE*[b](#tbl1fnb){ref-type="table-fn"}\   rs28573326\                POP stage ≥I                                                               POP stage = 0                                                 1427                              1274
                                                                                                                                                                      Intergenic                                 rs113518633                                                                                                                                                                                           

  Vishwajit et al[@bib60]       ICS abstract 2009                       United States                    Not stated                                                   *MMP1*                                     rs1799750                  SUI with varying POP                                                       Neither SUI nor POP                                           40                                15

  Wu et al[@bib54]              Am J Obstet Gynecol 2012                United States                    Non-Hispanic white                                           *LAMC1*                                    rs10911193\                POPQ ≥3                                                                    POPQ \<2                                                      239                               197
                                                                                                                                                                                                                 rs1413390\                                                                                                                                                                                            
                                                                                                                                                                                                                 rs20558\                                                                                                                                                                                              
                                                                                                                                                                                                                 rs20563\                                                                                                                                                                                              
                                                                                                                                                                                                                 rs10911206\                                                                                                                                                                                           
                                                                                                                                                                                                                 rs2296291\                                                                                                                                                                                            
                                                                                                                                                                                                                 rs12041030\                                                                                                                                                                                           
                                                                                                                                                                                                                 rs12739316\                                                                                                                                                                                           
                                                                                                                                                                                                                 rs3768617\                                                                                                                                                                                            
                                                                                                                                                                                                                 rs2483675\                                                                                                                                                                                            
                                                                                                                                                                                                                 rs10911211\                                                                                                                                                                                           
                                                                                                                                                                                                                 rs41475048\                                                                                                                                                                                           
                                                                                                                                                                                                                 rs1058177\                                                                                                                                                                                            
                                                                                                                                                                                                                 rs12073936                                                                                                                                                                                            

  Wu et al[@bib63]              Obstet Gynecol 2012                     United States                    Non-Hispanic white                                           *MMP9*                                     rs3918253\                 POPQ ≥3                                                                    POPQ \<2                                                      239                               197
                                                                                                                                                                                                                 rs3918256\                                                                                                                                                                                            
                                                                                                                                                                                                                 rs3918278\                                                                                                                                                                                            
                                                                                                                                                                                                                 rs17576\                                                                                                                                                                                              
                                                                                                                                                                                                                 rs2274755\                                                                                                                                                                                            
                                                                                                                                                                                                                 rs17577\                                                                                                                                                                                              
                                                                                                                                                                                                                 rs2236416\                                                                                                                                                                                            
                                                                                                                                                                                                                 rs3787268                                                                                                                                                                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*AUA*, American Urological Association; *ICS*, International Continence Society; *IUGA*, International Urogynecological Association; *LUTS*, lower urinary tract symptoms; *OAB*, overactive bladder; *POP*, pelvic organ prolapse; *POPQ*, Pelvic Organ Prolapse Quantification system; *SNP*, single-nucleotide polymorphism; *SUI*, stress urinary incontinence; *UI*, urinary incontinence; *UUI*, urge urinary incontinence.

*Cartwright. Genetic association studies of LUTS and POP. Am J Obstet Gynecol 2015*.

Assessments of descent/ethnicity/race as specified in primary publications, or from additional data from authors, or assumed for countries with low ethnic heterogeneity including Taiwan, Korea, and Japan

Genome-wide significant genes (*P* \<5 × 10^-8^) reported in genome-wide association study.

###### 

Interim Venice assessments of epidemiological credibility for each metaanalysis

  Gene          SNP          Phenotype   Studies, n   Sample with minor allele[a](#tbl2fna){ref-type="table-fn"}   Pooled OR   I^2^ %   Deviation from HWE[b](#tbl2fnb){ref-type="table-fn"}   Proteus effect   Harbord test *P* value   Funnel plot                                             Genotyping QC                                      Risk of population stratification               Venice rating   Overall credibility
  ------------- ------------ ----------- ------------ ------------------------------------------------------------ ----------- -------- ------------------------------------------------------ ---------------- ------------------------ ------------------------------------------------------- -------------------------------------------------- ----------------------------------------------- --------------- ---------------------
  *ADRB3*       rs4994       OAB         2            136                                                          2.46        0.0      None                                                   None             n/a                      n/a                                                     Not reported                                       Yes[@bib38][c](#tbl2fnc){ref-type="table-fn"}   BBB             Moderate
  *COL1A1*      rs1800012    SUI         2            92                                                           2.09        0.0      Yes[@bib46]                                            None             n/a                      n/a                                                     Not reported                                       Low                                             CBC             Weak
  POP           4            249         1.33         0.0                                                          None        None     .88                                                    Symmetric        Not reported             Yes[@bib41; @bib42][c](#tbl2fnc){ref-type="table-fn"}   BBB                                                Moderate                                                        
  *COL3A1*      rs1800255    POP         2            257                                                          1.19        0.0      None                                                   Yes              n/a                      n/a                                                     Not reported[@bib49]/appropriate[@bib50]           None                                            BCB             Weak
  rs111929073   POP          2           115          0.56                                                         83.7        None     None                                                   n/a              n/a                      Not reported                                            Yes[@bib52][c](#tbl2fnc){ref-type="table-fn"}      BCB                                             Weak            
  *LAMC1*       rs10911193   POP         4            218                                                          1.12        0.0      None                                                   None             .97                      Symmetric                                               Appropriate[@bib54; @bib55]/not reported[@bib56]   Low                                             BCB             Weak
  rs20563       POP          3           525          1.12                                                         0.0         None     None                                                   .86              Symmetric                Appropriate                                             Low                                                BCA                                             Weak            
  rs20558       POP          3           551          1.12                                                         0.0         None     None                                                   .93              Symmetric                Appropriate                                             Low                                                BCA                                             Weak            
  *MMP1*        rs1799750    POP         2            234                                                          0.83        74.9     Yes[@bib61]                                            Yes              n/a                      n/a                                                     Not reported                                       Low                                             BCC             Weak
  SUI           2            150         0.88         3.4                                                          None        None     n/a                                                    n/a              Not reported             Yes[@bib60][c](#tbl2fnc){ref-type="table-fn"}           BCC                                                Weak                                                            
  *MMP3*        rs3025058    POP         2            381                                                          1.11        0.0      Yes[@bib61]                                            None             n/a                      n/a                                                     Not reported                                       Low                                             BCC             Weak
  *MMP9*        rs3918242    POP         2            99                                                           1.25        0.0      None                                                   None             n/a                      n/a                                                     Not reported                                       Low                                             CCC             Weak
  rs17576       POP          3           473          1.05                                                         68.9        None     None                                                   .72              Symmetric                Not reported[@bib57]/appropriate[@bib54]                Low                                                BCB                                             Weak            

Three-letter code corresponds to A through C ratings of amount of evidence, its consistency, and its protection from bias ([Supplementary Figure](#appsec1){ref-type="sec"}).

*HWE*, Hardy Weinberg Equilibrium; *OAB*, overactive bladder; *OR*, odds ratio; *POP*, pelvic organ prolapse; *QC*, quality control; *SNP*, single-nucleotide polymorphism; *SUI*, stress urinary incontinence.

*Cartwright. Genetic association studies of LUTS and POP. Am J Obstet Gynecol 2015*.

Pooled sample size of participants with minor allele

Checked in controls and whole population, and metaanalysis rechecked excluding studies with significant departure

Studies each include populations with mixed descent groups without reported adjustment.

[^1]: Functions assigned from <http://david.abcc.ncifcrf.gov>.

    *Cartwright. Genetic association studies of LUTS and POP. Am J Obstet Gynecol 2015*.

[^2]: All processes significant at *P* \< .01, analysis using <http://webclu.bio.wzw.tum.de/profcom/>. Overrepresented Gene Ontology: <http://www.geneontology.org>.

    *Cartwright. Genetic association studies of LUTS and POP. Am J Obstet Gynecol 2015*.
